Treatment options for retinal diseases, such as neovascular age-related macular
degeneration, diabetic retinopathy, and retinal vascular disorders, have markedly expanded …

The eye is a distinctive organ with protective anatomy and physiology. Several
pharmacokinetics compartment models of ocular drug delivery have been developed for …

Background Despite increasing worldwide use of anti-vascular endothelial growth factor
agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular …

Purpose: To evaluate the systemic pharmacokinetics (PKs) of aflibercept, bevacizumab, and
ranibizumab in patients with neovascular age-related macular degeneration (AMD), diabetic …

Background Data comparing systemic exposure and systemic vascular endothelial growth
factor (VEGF) suppression of ranibizumab, bevacizumab and aflibercept following …

Clinical efficacy of intravitreal anti-VEGF drugs has been widely demonstrated in several
angiogenesis-driven eye diseases including diabetic macular edema and the neovascular …

This review highlights how hydrogel formulations can improve intravitreal protein delivery to
the posterior segment of the eye in order to increase therapeutic outcome and patient …

The impact of proteins and peptides on the treatment of various conditions including ocular
diseases over the past few decades has been advanced by substantial breakthroughs in …

Neovascular age-related macular degeneration (NVAMD) is the most prevalent choroidal
vascular disease, and diabetic retinopathy (DR) and retinal vein occlusion (RVO) are the …

Background Neovascular age‐related macular degeneration (AMD) is the leading cause of
legal blindness in elderly populations of industrialised countries. Bevacizumab (Avastin®) …